Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06063473 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris
A Phase 1 study of Acne Vulgaris, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 762
- Enrollment target
- 1
- Study location
NCT06063473: Completed Phase 1 study of Acne Vulgaris, sponsored by Sun Pharmaceutical Industries.
NCT06063473 is a Phase 1 study of Acne Vulgaris that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 762 participants, above the 264-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (189% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06063473, a Phase 1 study of Acne Vulgaris, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 762 participants
- Enrollment target
- 1
- Study location
Study Summary
To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris
Primary Outcome
Percent change in the inflammatory (papules and pustules) \& non-inflammatory (open and closed comedones) lesion counts
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Trifarotene Cream 0.005%
- DRUG AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)
Study Locations (1)
New York
- Taro Pharmaceuticals USA Inc. - Hawthorne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 762 participants |
| Start Date | 2023-02-22 |
| Est. Completion | 2023-07-13 |
| Phase | Phase 1 |
What the finished NCT06063473 record still lists
NCT06063473 is an interventional study that assigns participants to a tested intervention. The registered 762 participants enrollment target is mid-sized for trials with a published cap, above the 264-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (189% higher).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06063473 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06063473 about?
NCT06063473 is a clinical study titled "A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris". To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris
What is the current status of trial NCT06063473?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 762 participants. The study started on 2023-02-22. Estimated completion is 2023-07-13.
What conditions does trial NCT06063473 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT06063473?
The interventions under investigation include: Placebo (DRUG), Trifarotene Cream 0.005% (DRUG), AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories) (DRUG).
Who is sponsoring clinical trial NCT06063473?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06063473 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06063473's enrollment target sits among peer trials
762 5th of 67 higher than 63 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
RECRUITING · Phase 1
-
Lipidome and Microbiome Profile of Acne
ACTIVE NOT RECRUITING · Phase 1
-
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
COMPLETED · Phase 1
-
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
COMPLETED · Phase 1
-
A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204
COMPLETED · Phase 1
-
A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06419374 · 762 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- NCT04578665 · 764 participants · NA
Human-like Robotic Controllers for Enhanced Motor Learning
- NCT05579366 · 764 participants · Phase 1
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- NCT02089607 · 760 participants · NA
CAAAs, TAAAs, Aortic Arch Aneurysms or Dissections With Fenestrated/Branched Stent Graft
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI